IP Library Granted Patent US 10,117,846
Granted Patent B2
US 10,117,846 · App. 15/704,219 · Granted Nov 6, 2018

Prodrugs of fumarates and their use in treating various diseases

Inventors: Tarek A. Zeidan (Lexington, MA); Scott Duncan (Bedford, MA); Christopher P. Hencken (Boston, MA); Thomas Andrew Wynn (Lexington, MA); Carlos N. Sanrame (Lexington, MA)
Assignee: Alkermes Pharma Ireland Limited
A61K31/225C07C219/08C07C229/16C07C233/18C07C233/91C07C317/18C07C317/28C07D207/06C07D207/40C07D209/52C07D211/06C07D211/38C07D295/088C07D491/113
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,117,846
App. No.
15/704,219
Granted
Nov 6, 2018
Kind
B2
Abstract

The present invention provides compounds of formula (I), and pharmaceutical compositions thereof.

Claims (16)

1. A pharmaceutical composition comprising a compound of Formula (Ia), or a pharmaceutically acceptable salt thereof:

wherein:

R 1 is unsubstituted C 1 -C 6 alkyl;

L a is unsubstituted C 1 -C 6 alkyl linker; and

R 2 is H, unsubstituted C 1 -C 6 alkyl, unsubstituted C 2 -C 6 alkenyl, or unsubstituted C 2 -C 6 alkynyl; and

a pharmaceutically acceptable carrier.

2. The composition of claim 1 , wherein R 1 is methyl.

3. The composition of claim 1 , wherein L a is an unsubstituted C 1 -C 3 alkyl.

4. The composition of claim 3 , wherein L a is an unsubstituted C 2 alkyl.

5. The composition of claim 1 , wherein R 2 is an unsubstituted C 1 -C 6 alkyl, unsubstituted C 2 -C 6 alkenyl, or unsubstituted C 2 -C 6 alkynyl.

6. The composition of claim 5 , wherein R 2 is an unsubstituted C 1 -C 6 alkyl.

7. The composition of claim 6 , wherein R 2 is an unsubstituted C 1 -C 3 alkyl.

8. The composition of claim 7 , wherein R 2 is an unsubstituted C 1 -C 2 alkyl.

9. The composition of claim 8 , wherein R 2 is methyl.

10. The composition of claim 1 , wherein the compound of Formula (Ia) has the structure:

 or a pharmaceutically acceptable salt thereof.

Assignments (6)
SECURITY INTEREST Recorded Feb 13, 2026
From: ALKERMES PHARMA IRELAND LIMITED
To: JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT
Reel/Frame 074858/0405 →
RELEASE OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (073213/0302) Recorded Feb 13, 2026
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 074858/0429 →
SECURITY INTEREST Recorded Oct 23, 2025
From: ALKERMES PHARMA IRELAND LIMITED
To: JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT
Reel/Frame 073213/0302 →
SECURITY INTEREST Recorded Mar 20, 2020
From: ALKERMES PHARMA IRELAND LIMITED
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 052914/0832 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 23, 2019
From: ZEIDAN, TAREK A.; DUNCAN, SCOTT; HENCKEN, CHRISTOPHER P.; WYNN, THOMAS ANDREW; SANRAME, CARLOS N.
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 051354/0700 →
SECURITY INTEREST Recorded Dec 4, 2018
From: ALKERMES PHARMA IRELAND LIMITED
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 047671/0386 →
Continuity (5)
Continuation 15295370 · Oct 17, 2016
Continuation 14212745 · Mar 14, 2014
Provisional Application 61934365 · Jan 31, 2014
Provisional Application 61782445 · Mar 14, 2013
Related Publication 20180064673A1 · Mar 8, 2018